Definium Therapeutics (DFTX) Other Non Operating Income (2021 - 2026)
Definium Therapeutics' (DFTX) quarterly Other Non Operating Income came in at -$17.9 million in Q1 2026, down 93994.74% year-on-year from N/an in Q1 2025, and down 45741.03% on a QoQ basis from -$39000.0 in Q3 2025.
Definium Therapeutics (DFTX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 6 years of Other Non Operating Income data on file, last reported at -$17.9 million in Q1 2026.
- On a quarterly basis, Other Non Operating Income fell 93994.74% year-over-year to -$17.9 million in Q1 2026; TTM through Mar 2026 was -$19.8 million, a 245.48% decrease from a year earlier, with the FY2024 full-year figure at -$638000.0, changed N/A from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$17.9 million, down from -$39000.0 in the prior quarter.
- Over the last five years, Other Non Operating Income for DFTX reached as high as $11.1 million in Q3 2024 and fell as low as -$32.2 million in Q1 2024.
- Historically, Other Non Operating Income has averaged -$2.7 million across 5 years, with a median of -$29000.0 in 2025.
- Across the five-year window, Other Non Operating Income surged 4605.56% in 2024 and plunged 93994.74% in 2026, its largest moves.
- Year by year, Other Non Operating Income stood at -$343000.0 in 2022, then jumped by 171.14% to $244000.0 in 2023, then slumped by 120.08% to -$49000.0 in 2024, then grew by 20.41% to -$39000.0 in 2025, then sank by 45741.03% to -$17.9 million in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$17.9 million in Q1 2026, -$39000.0 in Q3 2025, and -$1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Definium Therapeutics | 4.71 Bn | 4.71 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.88 Mn |
| Sep 30, 2025 | -39,000.00 |
| Jun 30, 2025 | -1.84 Mn |
| Mar 31, 2025 | -19,000.00 |
| Dec 31, 2024 | -49,000.00 |
| Sep 30, 2024 | 11.11 Mn |
| Jun 30, 2024 | 2.54 Mn |
| Mar 31, 2024 | -32.20 Mn |
| Dec 31, 2023 | 244,000.00 |
| Sep 30, 2023 | -439,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | -3.95 Mn |
| Dec 31, 2022 | -343,000.00 |
| Sep 30, 2022 | 138,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | 54,000.00 |
| Dec 31, 2021 | -180,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Jun 30, 2021 | -32,000.00 |
| Mar 31, 2021 | 8,000.00 |